Skip to main content
. 2022 Feb;10(4):188. doi: 10.21037/atm-22-412

Figure 1.

Figure 1

Percentages of patients with lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) carrying different classes of TP53 mutations.